Drug Database · Clinicians

Palonosetron

Brands (23) Aloxi, Blissetron, Emecad…Show all

US brand (reference label): palonosetron hydrochloride; not a Philippine-registered brand.

Antiemetic/Antinauseant [serotonin (5HT3) antagonist]; Anti-emetic/Anti-nauseant [serotonin (5HT3) antagonist]; and others PH FDA category

Rx · Prescription drug25 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 37e7ef89-fd77-44e0-9271-ae91f8822603, version date January 13, 2022 (palonosetron hydrochloride · Cipla USA Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Moderately emetogenic cancer chemotherapy - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1 .1) Highly emetogenic cancer chemotherapy - prevention of acute nausea and…
  • Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.
  • Prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3) receptor antagonist indicated in adults for: Moderately emetogenic cancer chemotherapy - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses (1 .1) Highly emetogenic cancer chemotherapy - prevention of acute nausea and vomiting associated with initial and repeat courses (1.1) Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated (1.3) Palonosetron Hydrochloride Injection is indicated in pediatric patients aged 1 month to less than 17 years for: Prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (1.2) 1.1 Chemotherapy-Induced Nausea and Vomiting in Adults Palonosetron Hydrochloride Injection is indicated for: Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses 1.2 Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Aged 1 Month to Less than 17 Years Palonosetron Hydrochloride Injection is indicated for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. 1.3 Postoperative Nausea and Vomiting in Adults Palonosetron Hydrochloride Injection is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.

Contraindications

4 CONTRAINDICATIONS Palonosetron Hydrochloride Injection is contraindicated in patients known to have hypersensitivity to the drug or any of its components. [see Adverse Reactions (6.2)]. Palonosetron Hydrochloride Injection is contraindicated in patients known to have hypersensitivity to the drug or any of its components (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Chemotherapy-Induced Nausea and Vomiting (2.1)
  • *Note different dosing units in pediatrics Age Dose* Infusion Time Adults 0. 2 5 mg x 1 Infuse over 30 seconds beginning approx. 30 min before the start of chemo Pediatrics (1 month to less than 17 years) 2 0 micrograms per k ilogram (max 1.5 mg) x 1 Infuse over 15 minutes beginning approx. 30 min before the start of chemo Postoperative Nausea and Vomiting (2.1)
  • Adult Dosage: a single 0.075 mg intravenous dose administered over 10 seconds immediately before the induction of anesthesia.
2.1 Recommended Dosing Chemotherapy-Induced Nausea and Vomiting

2.1 Recommended Dosing Chemotherapy-Induced Nausea and Vomiting *Note different dosing units in pediatrics Age Dose* Infusion Time Adults 0. 2 5 mg x 1 Infuse over 30 seconds beginning approx. 30 min before the start of chemo Pediatrics (1 month to less than 17 years) 2 0 micrograms per kilogram (max 1.5 mg) x 1 Infuse over 15 minutes beginning approx. 30 min before the start of chemo Postoperative Nausea and Vomiting Dosage for Adults - a single 0.075 mg intravenous dose administered over 10 seconds immediately before the induction of anesthesia.

2.2 Instructions for Intravenous Administration

2.2 Instructions for Intravenous Administration Palonosetron Hydrochloride Injection is supplied ready for intravenous administration at a concentration of 0.05 mg/mL (50 mcg/ mL). Palonosetron Hydrochloride Injection should not be mixed with other drugs. The infusion line should be flushed with normal saline before and after administration of Palonosetron Hydrochloride Injection.

Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters. Total systemic exposure increased by approximately 28% in severe renal impairment relative to healthy subjects. Dosage adjustment is not necessary in patients with any degree of renal impairment.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects. Dosage adjustment is not necessary in patients with any degree of hepatic impairment.

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Chemotherapy-Induced Nausea and Vomiting Safety and effectiveness of Palonosetron Hydrochloride Injection have been established in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Use is supported by a clinical trial where 165 pediatric patients aged 2 months to <17 years were randomized to receive a single dose of palonosetron 20 mcg/kg (maximum 1.5 mg) administered as an intravenous infusion 30 minutes prior to the start of emetogenic chemotherapy [see Clinical Studies (14.2)].

While this study demonstrated that pediatric patients require a higher palonosetron dose than adults to prevent chemotherapy-induced nausea and vomiting, the safety profile is consistent with the established profile in adults [see Adverse Reactions (6.1)]. Safety and effectiveness of Palonosetron Hydrochloride Injection in neonates (less than 1 month of age) have not been established.

Postoperative Nausea and Vomiting Studies Safety and efficacy have not been established in pediatric patients for prevention of postoperative nausea and vomiting. Two pediatric trials were performed. Pediatric Study 1, a dose finding study was conducted to compare two doses of palonosetron, 1 mcg/kg (max 0.075 mg) versus 3 mcg/kg (max 0.25 mg).

A total of 150 pediatric surgical patients participated, age range 1 month to <17 years. No dose response was observed. Pediatric Study 2, a multicenter, double-blind, double-dummy, randomized, parallel group, active control, single-dose non-inferiority study, compared I.V. palonosetron (1 mcg/kg, max 0.075 mg) versus I.V. ondansetron.

A total of 670 pediatric surgical patients participated, age 30 days to <17 years. The primary efficacy endpoint, Complete Response (CR: no vomiting, no retching, and no antiemetic rescue medication) during the first 24 hours postoperatively was achieved in 78.2% of patients in the palonosetron group and 82.7% in the ondansetron group.

Given the pre-specified non-inferiority margin of -10%, the stratum adjusted Mantel-Haenszel statistical non-inferiority confidence interval for the difference in the primary endpoint, complete response (CR), was [-10.5, 1.7%], therefore non-inferiority was not demonstrated. Adverse reactions to palonosetron were similar to those reported in adults (Table 2).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Population pharmacokinetics analysis did not reveal any differences in palonosetron pharmacokinetics between cancer patients ≥ 65 years of age and younger patients (18 to 64 years). Of the 1374 adult cancer patients in clinical studies of palonosetron, 316 (23%) were ≥ 65 years old, while 71 (5%) were ≥ 75 years old.

No overall differences in safety or effectiveness were observed between these subjects and the younger subjects, but greater sensitivity in some older individuals cannot be ruled out. No dose adjustment or special monitoring are required for geriatric patients. Of the 1520 adult patients in Palonosetron Hydrochloride Injection PONV clinical studies, 73 (5%) were ≥ 65 years old.

No overall differences in safety were observed between older and younger subjects in these studies, though the possibility of heightened sensitivity in some older individuals cannot be excluded. No differences in efficacy were observed in geriatric patients for the CINV indication and none are expected for geriatric PONV patients.

However, Palonosetron Hydrochloride Injection efficacy in geriatric patients has not been adequately evaluated.

Administration

2.2 Instructions for Intravenous Administration Palonosetron Hydrochloride Injection is supplied ready for intravenous administration at a concentration of 0.05 mg/mL (50 mcg/ mL). Palonosetron Hydrochloride Injection should not be mixed with other drugs. The infusion line should be flushed with normal saline before and after administration of Palonosetron Hydrochloride Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit.

US FDA label

Dosage forms

Philippines

  • ) solution for intravenous injection: 50 mcg/mL (250 mcg 15 mL, 50 mcg/mL (250 mcg/5 mL
  • ) solution for injection: 50 mcg/mL (250 mcg/5 mL, 50 mcg/mL (250 mcg/mL
  • ) solution for i.v. injection: 50 mcg/mL (250 mcg/5 mL, 50 mcg/mL (75 mcg/1.5 mL
  • Solution for injection: 250 mcg/mL

Registered products in the Philippines

25 products registered with the Food and Drug Administration (FDA) Philippines list Palonosetron as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products25
Philippine FDA-registered products for Palonosetron
Package insert
AloxiPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/ 5mL) Solution for Intravenous Injection5 mL (net content) USP Type I clear and colorless glass vial with gray chlorobutyl rubber stopper and aluminum/propylene flip-off seal (Box of 1 vial)
RxVAT-exempt
Fareva PauFrance
Importer: DKSH Market Expansion Services Philippines, Inc.
DR-XY42192
Jul 3, 2028
AloxiPalonosetron (as hydrochloride)
50mcg/mL (75mcg/1.5mL) Solution for I.V. Injection1.5 mL Net Content in 3mL-Capacity USP Type I Clear and Colorless Glass Vial with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Orange PP Flip-Off Cap Box of 5's
RxVAT-exempt
Fareva PauFrance
Importer: DKSH Market Expansion Services Philippines, Inc.
DR-XY43357
May 5, 2029
BlissetronPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/mL) Solution for Injection (IV)10 mL Type I Clear Colorless Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Fill-off Seal Cap x 5 mL (Net Content) (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.Trader: Seacross Pharmaceuticals Ltd.
DRP-12598-01
Sep 12, 2027
EmecadPalonosetron Hydrochloride
250 mcg/mL Solution for InjectionType I glass vial x 5 mL with brown bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
RxVAT-exempt
Cadila Pharmaceuticals LimitedIndia
S.M.H.P. Marketing & Consultancy
DRP-17312
Nov 14, 2030
FerantPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous InjectionType I clear glass ampoule x 5 mL (Box of l’s)
RxVAT-exempt
Medochemie Ltd. (Ampoule Injectable Facility)Cyprus
Detoxicare Philippines Inc.
DRP-12361
Jul 25, 2027
LonoxiePalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous Injection5 mL (net content) USP/Ph. Eur. Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue flip-off cap (box of 1 vial)
RxVAT-exempt
USV Private LimitedIndia
I.E. Medica, Inc.
DRP-11119
Feb 4, 2027
Lonset IVPalonosetron (As Hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Injection (IV)10 mL Type I Clear Colorless Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Flip Off Seal Cap x 5 mL (Net content) (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Bliss Pharma Distribution and Consultancy Corp.
DRP-12598
Sep 12, 2027
MednosetronPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous InjectionUSP Type I clear glass ampoule x 5 mL (Box of 1’s)
RxVAT-exempt
Reyoung Pharmaceutical Co., Ltd.China
Medinfinity Inc.Importer: AMB HK Enterprises Inc.
DRP-15494-01
Aug 12, 2029
MilovanPalonosetron (as hydrochloride)
50mcg/mL (250mcg/5mL) Solution for Intravenous Injection5mL (net content) USP/Ph. Eur. Type I clear and colorless glass vial gray bromobutyl rubber stopper and aluminum seal with blue flip-off (Box of 1's)
RxVAT-exempt
USV Private LimitedIndia
Kaufmann Pharma Inc.Importer: I.E. Medica, Inc.
DRP-11119-03
Feb 4, 2027
NausiabenePalonosetron (as hydrochloride)
50 mcg / mL (250 mcg / 5 mL) Solution for Intravenous Injection5 mL (net content) USP/Ph. Eur. Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue flip-off cap (Box of 1 vial)
RxVAT-exempt
USV Private LimitedIndia
MedEthix, Inc.Importer: I.E. Medica, Inc.
DRP-11119-02
Feb 4, 2027
NosetrinovPalonosetron Hydrochloride
50 mcg/mL (250 mcg/5 mL) Solution For InjectionType I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with White Flip-off Cap x 5 mL (Box of 1's)
RxVAT-exempt
Shree Anand Lifesciences, Ltd.India
Medinova Pharmaceutical Inc.
DRP-19084
Oct 26, 2031
PalnosPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg 15 mL) Solution for Intravenous Injection5 mL USP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum seal and blue PP flip off cap (Box of 1's)
RxVAT-exempt
PT. Ferron Par PharmaceuticalsIndonesia
Glorious Dexa Mandaya, Inc.
DRP-12083
Jun 10, 2027
PalnostarPalonosetron (as hydrochloride)
50 mcg/mL (250mcg/5mL) Solution for Injection (IV)10 mL Type I Clear Colorless Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Flip Off Seal cap x 5mL (Net Content) (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Pharmastar Int'l Trading Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.Trader: Seacross Pharmaceuticals Ltd.
DRP-12598-03
Sep 12, 2027
PaloGetPalonosetron hydrochloride
50 mcg / mL (250 mcg / 5 mL) Solution for Intravenous Injection6 mL USP Type I clear glass vial (5 mL net content with chlorobutyl rubber stopper and aluminum seal and violet flip off cap (Box of 1's)
RxVAT-exempt
Intas Pharmaceutical LimitedIndia
Getmeds Philippines Inc.Importer: Accord Healthcare Limited - Philippine Branch Office
DRP-12167-01
Jun 23, 2027
PalonanPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for I.V. Injection6R Type I glass vial
RxVAT-exempt
ANFARM HELLAS S.A.Greece
Aglobal Care, Inc.
DRP- 17995
Apr 21, 2031
PalonolifePalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution For Injection (I.V.)1.5 mL & 5 ml USP Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum seal and blue Flip-off Cap (Box of 1's)
RxVAT-exempt
Anhil Parenterals Pvt. Ltd.India
Biophil Medical Equipment and Supplies Trading
DRP-18081
Sep 21, 2032
PalosetPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5mL) Solution for Injection (IV)USP Type I clear glass vial with grey bromobutyl stopper and aluminum flip-off seal x 5 mL (Box of 10's)
RxVAT-exempt
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-12139
Jun 20, 2027
PalotronPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous InjectionUSP Type I clear glass ampoule x 5 mL(Box of 1's)
RxVAT-exempt
Reyoung Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-15494
Aug 12, 2029
PalsetPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg 15 mL) Solution for Intravenous Injection6 mL USP Type I clear glass vial (5 mL net content) with chlorobutyl rubber stopper and aluminum seal and violet flip off cap (Box of l’s)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DRP-12167
Jun 23, 2027
PalvotronPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/ 5 mL) Solution for I.V. InjectionUSP Type I clear colourless glass vial with 20 mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip off Seal x 5 mL (Box of 1's).
RxVAT-exempt
USV Private LimitedIndia
Macropharma Corporation.
DRP-13565
Mar 9, 2028
PaulonorestPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous InjectionType I Clear and colorless glass vial with chlorobutyl rubber stopper and red-colored aluminum flip-off seal x 5 mL (Box of 1's)
RxVAT-exempt
Sichuan Huiyi Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17239
Oct 23, 2030
QualitronPalonosetron (as hydrochloride)
50 mcg / mL (250 mcg/5 mL) Solution for Injection (IV)10 mL Type I Clear Colorless Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Flip-off Seal Cap x 5 mL (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Qualimed Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.Trader: Seacross Pharmaceuticals Ltd.
DRP-12598-04
Sep 12, 2027
SepalonPalonosetron Hydrochloride
50 mcg/mL (250 mcg/mL) Solution for Injection (IV)10 mL Type I Clear Colorless Glass Vial sealed with Gray Chlorobutyl Rubber Stopper and Aluminum flip-off seal cap x 5 mL (Net content) (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Amediqo Phils., Inc.Importer: Bliss Pharma Distribution And Consultancy Corp.
DRP-12598-02
Sep 12, 2027
X-NoseiaPalonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous Injection5 mL (net content) USP/Ph. Eur. Type I Clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue flip-off cap (Box of 1 vial)
RxVAT-exempt
USV Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-11119-01
Feb 4, 2027
(no brand name)Palonosetron (as hydrochloride)
50 mcg/mL (250 mcg/5 mL) Solution for Intravenous Injection5 mL (net content) USP/Ph. Eur. Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue flip-off cap (box of 1 vial)
RxVAT-exempt
USV Private LimitedIndia
I.E. Medica, Inc.
DRP-11120
Feb 4, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORM AND STRENGTHS Palonosetron Hydrochloride Injection is supplied as a single-use sterile, clear, colorless solution in glass vials that provide: 0.25 mg (free base) per 5 mL (concentration: 0.05 mg/mL, 50 mcg/mL) 0.25 mg/5mL (free base) single-use vial (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other selective 5-HT 3 receptor antagonists (5.1)
  • Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs (5.2)
5.1 Hypersensitivity

5.1 Hypersensitivity Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT 3 receptor antagonists.

5.2 Serotonin Syndrome

5.2 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).

Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT 3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT 3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Palonosetron Hydrochloride Injection and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Palonosetron Hydrochloride Injection and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Palonosetron Hydrochloride Injection is used concomitantly with other serotonergic drugs [see Drug Interactions (7), Patient Counseling Information (17)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Palonosetron is eliminated from the body through both renal excretion and metabolic pathways with the latter mediated via multiple CYP enzymes. Further in vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5.

Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low. Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.2)].

Coadministration of 0.25 mg I.V. palonosetron and 20 mg I.V. dexamethasone in healthy subjects revealed no pharmacokinetic drug-interactions between palonosetron and dexamethasone. In an interaction study in healthy subjects where palonosetron 0.25 mg (I.V. bolus) was administered on day 1 and oral aprepitant for 3 days (125 mg/80 mg/80 mg), the pharmacokinetics of palonosetron were not significantly altered (AUC: no change, C max: 15% increase).

A study in healthy volunteers involving single-dose I.V. palonosetron (0.75 mg) and steady state oral metoclopramide (10 mg four times daily) demonstrated no significant pharmacokinetic interaction. In controlled clinical trials, Palonosetron Hydrochloride Injection has been safely administered with corticosteroids, analgesics, antiemetics /antinauseants, antispasmodics and anticholinergic agents.

Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models. The potential for clinically significant drug interactions with palonosetron appears to be low (7)

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron.

However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.

Further in vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5.

Adverse reactions

Adverse reactions (US label) US FDA label

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions in chemotherapy-induced nausea and vomiting in adults (incidence ≥5%) are headache and constipation (6.1).

The most common adverse reactions in postoperative nausea and vomiting (incidence ≥ 2%) are QT prolongation, bradycardia, headache, and constipation (6.2). To report SUSPECTED ADVERSE REACTIONS, contact Cipla USA, Inc., at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Chemotherapy-Induced Nausea and Vomiting Adults

6.1 Chemotherapy-Induced Nausea and Vomiting Adults In clinical trials for the prevention of nausea and vomiting induced by moderately or highly emetogenic chemotherapy, 1374 adult patients received palonosetron. Adverse reactions were similar in frequency and severity with Palonosetron Hydrochloride Injection and ondansetron or dolasetron.

Following is a listing of all adverse reactions reported by 2% of patients in these trials (Table 1). Table 1: Adverse Reactions from Chemotherapy-Induced Nausea and Vomiting Studies ≥ 2% in any Treatment Group Event Palonosetron Hydrochloride Injection 0.25 mg (N=633) Ondansetron 32 mg I.V. (N=410) Dolasetron 100 mg I.V.

(N=194) Headache 60 (9%) 34 (8%) 32 (16%) Constipation 29 (5%) 8 (2%) 12 (6%) Diarrhea 8 (1%) 7 (2%) 4 (2%) Dizziness 8 (1%) 9 (2%) 4 (2%) Fatigue 3 (< 1%) 4 (1%) 4 (2%) Abdominal Pain 1 (< 1%) 2 (< 1%) 3 (2%) Insomnia 1 (< 1%) 3 (1%) 3 (2%) In other studies, 2 subjects experienced severe constipation following a single palonosetron dose of approximately 0.75 mg, three times the recommended dose. One patient received a 10 mcg/kg oral dose in a post-operative nausea and vomiting study and one healthy subject received a 0.75 mg I.V. dose in a pharmacokinetic study.

In clinical trials, the following infrequently reported adverse reactions, assessed by investigators as treatment-related or causality unknown, occurred following administration of Palonosetron Hydrochloride Injection to adult patients receiving concomitant cancer chemotherapy: Cardiovascular: 1%: non-sustained tachycardia, bradycardia, hypotension, < 1%: hypertension, myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular extrasystoles and QT prolongation. In many cases, the relationship to Palonosetron Hydrochloride Injection was unclear.

Dermatological: < 1%: allergic dermatitis, rash. Hearing and Vision: < 1%: motion sickness, tinnitus, eye irritation and amblyopia. Gastrointestinal System: 1%: diarrhea, < 1%: dyspepsia, abdominal pain, dry mouth, hiccups and flatulence. General: 1%: weakness, < 1%: fatigue, fever, hot flash, flu-like syndrome. Liver: < 1%: transient, asymptomatic increases in AST and/or ALT and bilirubin.

These changes occurred predominantly in patients receiving highly emetogenic chemotherapy. Metabolic: 1%: hyperkalemia, < 1%: electrolyte fluctuations, hyperglycemia, metabolic acidosis, glycosuria, appetite decrease, anorexia. Musculoskeletal: < 1%: arthralgia. Nervous System: 1%: dizziness, < 1%: somnolence, insomnia, hypersomnia, paresthesia.

Psychiatric: 1%: anxiety, < 1%: euphoric mood. Urinary System: < 1%: urinary retention. Vascular: < 1%: vein discoloration, vein distention. Pediatrics In a pediatric clinical trial for the prevention of chemotherapy-induced nausea and vomiting 163 cancer patients received a single 20 mcg/kg (maximum 1.5 mg) intravenous infusion of palonosetron 30 minutes before beginning the first cycle of emetogenic chemotherapy.

Patients had a mean age of 8.4 years (range 2 months to 16.9 years) and were 46% male; and 93% white. The following adverse reactions were reported for palonosetron: Nervous System: <1%: headache, dizziness, dyskinesia. General: <1%: infusion site pain. Dermatological: <1%: allergic dermatitis, skin disorder. In the trial, adverse reactions were evaluated in pediatric patients receiving palonosetron for up to 4 chemotherapy cycles.

6.2 Postoperative Nausea and Vomiting

6.2 Postoperative Nausea and Vomiting The adverse reactions cited in Table 2 were reported in ≥ 2% of adults receiving I.V. Palonosetron Hydrochloride Injection 0.075 mg immediately before induction of anesthesia in one phase 2 and two phase 3 randomized placebo-controlled trials. Rates of events between palonosetron and placebo groups were similar.

Some events are known to be associated with, or may be exacerbated by concomitant perioperative and intraoperative medications administered in this surgical population. Please refer to Section 12.2, thorough QT/QTc study results, for data demonstrating the lack of palonosetron effect on QT/QTc. Table 2: Adverse Reactions from Postoperative Nausea and Vomiting Studies ≥ 2% in any Treatment Group Event Palonosetron Hydrochloride Injection 0.075 mg (N=336) Placebo (N=369) Electrocardiogram QT prolongation 16 (5%) 11 (3%) Bradycardia 13 (4%) 16 (4%) Headache 11 (3%) 14 (4%) Constipation 8 (2%) 11(3%) In these clinical trials, the following infrequently reported adverse reactions, assessed by investigators as treatment-related or causality unknown, occurred following administration of Palonosetron Hydrochloride Injection to adult patients receiving concomitant perioperative and intraoperative medications including those associated with anesthesia: Cardiovascular: 1%: electrocardiogram QTc prolongation, sinus bradycardia, tachycardia, < 1%: blood pressure decreased, hypotension, hypertension, arrhythmia, ventricular extrasystoles, generalized edema, ECG T wave amplitude decreased, platelet count decreased.

The frequency of these adverse effects did not appear to be different from placebo. Dermatological: 1%: pruritus. Gastrointestinal System: 1%: flatulence, < 1%: dry mouth, upper abdominal pain, salivary hypersecretion, dyspepsia, diarrhea, intestinal hypomotility, anorexia. General: < 1%: chills. Liver: 1%: increases in AST and/or ALT, < 1%: hepatic enzyme increased.

Metabolic: < 1%: hypokalemia, anorexia. Nervous System: < 1%: dizziness. Respiratory: < 1%: hypoventilation, laryngospasm. Urinary System: 1%: urinary retention.

6.3 Postmarketing Experience

6.3 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Palonosetron Hydrochloride Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Very rare cases (<1/10,000) of hypersensitivity reactions including anaphylaxis and anaphylactic shock and injection site reactions (burning, induration, discomfort and pain) were reported from postmarketing experience of Palonosetron Hydrochloride Injection 0.25 mg in the prevention of chemotherapy-induced nausea and vomiting.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Adverse Reactions from Chemotherapy-Induced Nausea and Vomiting Studies ≥ 2% in any Treatment Group
Event Palonosetron Hydrochloride Injection 0.25 mg (N=633) Ondansetron 32 mg I.V. (N=410) Dolasetron 100 mg I.V. (N=194)
Headache 60 (9%) 34 (8%) 32 (16%)
Constipation 29 (5%) 8 (2%) 12 (6%)
Diarrhea 8 (1%) 7 (2%) 4 (2%)
Dizziness 8 (1%) 9 (2%) 4 (2%)
Fatigue 3 (< 1%) 4 (1%) 4 (2%)
Abdominal Pain 1 (< 1%) 2 (< 1%) 3 (2%)
Insomnia 1 (< 1%) 3 (1%) 3 (2%)
Table 2: Adverse Reactions from Postoperative Nausea and Vomiting Studies ≥ 2% in any Treatment Group
Event Palonosetron Hydrochloride Injection 0.075 mg (N=336) Placebo (N=369)
Electrocardiogram QT prolongation 16 (5%) 11 (3%)
Bradycardia 13 (4%) 16 (4%)
Headache 11 (3%) 14 (4%)
Constipation 8 (2%) 11(3%)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Category B Risk Summary Adequate and well controlled studies with Palonosetron Hydrochloride Injection have not been conducted in pregnant women. In animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron during the period of organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose in rats and rabbits, respectively.

Because animal reproduction studies are not always predictive of human response, Palonosetron Hydrochloride Injection should be used during pregnancy only if clearly needed. Animal Data In animal studies, no effects on embryo-fetal development were observed in pregnant rats given oral palonosetron at doses up to 60 mg/kg/day (1894 times the recommended human intravenous dose based on body surface area) or pregnant rabbits given oral doses up to 60 mg/kg/day (3789 times the recommended human intravenous dose based on body surface area) during the period of organogenesis.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers It is not known whether Palonosetron Hydrochloride Injection is present in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and the potential for tumorigenicity shown for palonosetron in the rat carcinogenicity study [see Nonclinical Toxicology (13.1)], a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Mechanism of action

12.1 Mechanism of Action Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema.

It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT 3 receptors located on vagal afferents to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factors and is triggered by release of 5-HT in a cascade of neuronal events involving both the central nervous system and the gastrointestinal tract.

The 5-HT 3 receptor has been demonstrated to selectively participate in the emetic response.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The effect of palonosetron on blood pressure, heart rate, and ECG parameters including QTc were comparable to ondansetron and dolasetron in CINV clinical trials. In PONV clinical trials the effect of palonosetron on the QTc interval was no different from placebo. In non-clinical studies palonosetron possesses the ability to block ion channels involved in ventricular de- and re‑polarization and to prolong action potential duration.

The effect of palonosetron on QTc interval was evaluated in a double blind, randomized, parallel, placebo and positive (moxifloxacin) controlled trial in adult men and women. The objective was to evaluate the ECG effects of I.V. administered palonosetron at single doses of 0.25, 0.75 or 2.25 mg in 221 healthy subjects. The study demonstrated no significant effect on any ECG interval including QTc duration (cardiac repolarization) at doses up to 2.25 mg.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

In healthy subjects, the total body clearance of palonosetron was 0.160 0.035 L/h/kg and renal clearance was 0.067 0.018 L/h/kg.

Mean terminal elimination half‑life is approximately 40 hours.

Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.

Table 3: Pharmacokinetics Parameters in Pediatric Cancer PatientsFollowing Intravenous Infusion of Palonosetron HydrochlorideInjection at 20 mcg/kg over 15 min a Geometric Mean (CV) except for t1/2 which is median values . b C T is the plasma palonosetron concentration at the end of the 15 minute infusion. c Clearance and Vss calculated from 10 and 20 mcg/kg and are weight adjusted.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics After intravenous dosing of palonosetron in healthy subjects and cancer patients, an initial decline in plasma concentrations is followed by a slow elimination from the body. Mean maximum plasma concentration (C max) and area under the concentration-time curve (AUC 0-∞) are generally dose-proportional over the dose range of 0.3–90 mcg/kg in healthy subjects and in cancer patients.

Following single I.V. dose of palonosetron at 3 mcg/kg (or 0.21 mg/70 kg) to six cancer patients, mean (± SD) maximum plasma concentration was estimated to be 5630 ± 5480 ng/L and mean AUC was 35.8 ± 20.9 h mcg/L. Following I.V. administration of palonosetron 0.25 mg once every other day for 3 doses in 11 cancer patients, the mean increase in plasma palonosetron concentration from Day 1 to Day 5 was 42±34%.

Following I.V. administration of palonosetron 0.25 mg once daily for 3 days in 12 healthy subjects, the mean (±SD) increase in plasma palonosetron concentration from Day 1 to Day 3 was 110±45%. After intravenous dosing of palonosetron in patients undergoing surgery (abdominal surgery or vaginal hysterectomy), the pharmacokinetic characteristics of palonosetron were similar to those observed in cancer patients.

Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg. Approximately 62% of palonosetron is bound to plasma proteins. Metabolism Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S-hydroxy-palonosetron.

These metabolites each have less than 1% of the 5-HT 3 receptor antagonist activity of palonosetron. In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.

Elimination After a single intravenous dose of 10 mcg/kg [14 C]-palonosetron, approximately 80% of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40% of the administered dose. In healthy subjects, the total body clearance of palonosetron was 0.160 0.035 L/h/kg and renal clearance was 0.067 0.018 L/h/kg.

Mean terminal elimination half‑life is approximately 40 hours. Specific Populations Pediatric Patients Single-dose I.V. Palonosetron Hydrochloride Injection pharmacokinetic data was obtained from a subset of pediatric cancer patients that received 10 mcg/kg or 20 mcg/kg. When the dose was increased from 10 mcg/kg to 20 mcg/kg a dose-proportional increase in mean AUC was observed.

Following single dose intravenous infusion of Palonosetron Hydrochloride Injection 20 mcg/kg, peak plasma concentrations (C T) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients < 6 years than in older patients. Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.

The total body clearance (L/h/kg) in patients 12 to 17 years old was similar to that in healthy adults. There are no apparent differences in volume of distribution when expressed as L/kg. Table 3: Pharmacokinetics Parameters in Pediatric Cancer PatientsFollowing Intravenous Infusion of Palonosetron HydrochlorideInjection at 20 mcg/kg over 15 min a Geometric Mean (CV) except for t1/2 which is median values. b C T is the plasma palonosetron concentration at the end of the 15 minute infusion. c Clearance and Vss calculated from 10 and 20 mcg/kg and are weight adjusted.

PK Parameter a Pediatric Age Group <2 y 2 to <6 y 6 to <12 y 12 to <17 y N=12 N=42 N=38 N=44 C T b, ng/L 9025 (197) 9414 (252) 16275 (203) 11831 (176) N=5 N=7 N=10 AUC 0-∞, h·mcg/L 103.5 (40.4) 98.7 (47.7) 124.5 (19.1) N=6 N=14 N=13 N=19 Clearance c, L/h/kg 0.31 (34.7) 0.23 (51.3) 0.19 (46.8) 0.16 (27.8) Vss c, L/kg 6.08 (36.5) 5.29 (57.8) 6.26 (40.0) 6.20 (29.0)

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. palonosetron hydrochloride · Cipla USA Inc. [US FDA-approved label, version 4, January 13, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37e7ef89-fd77-44e0-9271-ae91f8822603
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .